| 1. |
- Aad, G., et al.
(author)
-
- 2015
-
In: Journal of High Energy Physics. - : Springer. - 1029-8479 .- 1126-6708. ; :12
-
Journal article (peer-reviewed)
|
|
| 2. |
- Aad, G., et al.
(author)
-
- 2015
-
In: Journal of High Energy Physics. - : Springer-Verlag New York. - 1029-8479 .- 1126-6708. ; :6
-
Journal article (peer-reviewed)
|
|
| 3. |
- Aad, G., et al.
(author)
-
- 2015
-
In: Journal of High Energy Physics. - 1029-8479 .- 1126-6708. ; :1, s. 1-67
-
Journal article (peer-reviewed)
|
|
| 4. |
- Aad, G., et al.
(author)
-
- 2015
-
In: Journal of High Energy Physics. - : Springer. - 1029-8479 .- 1126-6708. ; :8
-
Journal article (peer-reviewed)
|
|
| 5. |
- Aad, G., et al.
(author)
-
- 2015
-
In: Journal of High Energy Physics. - 1029-8479 .- 1126-6708. ; :3
-
Journal article (peer-reviewed)
|
|
| 6. |
- Aad, G., et al.
(author)
-
- 2015
-
Journal article (peer-reviewed)
|
|
| 7. |
|
|
| 8. |
- Aad, G., et al.
(author)
-
- 2015
-
In: Physical Review C (Nuclear Physics). - 0556-2813 .- 1089-490X. ; 92:3
-
Journal article (peer-reviewed)
|
|
| 9. |
- Abolins, M., et al.
(author)
-
The ATLAS Data Acquisition and High Level Trigger system
- 2016
-
In: Journal of Instrumentation. - 1748-0221. ; 11
-
Journal article (peer-reviewed)abstract
- This paper describes the data acquisition and high level trigger system of the ATLAS experiment at the Large Hadron Collider at CERN, as deployed during Run 1. Data flow as well as control, configuration and monitoring aspects are addressed. An overview of the functionality of the system and of its performance is presented and design choices are discussed.
|
|
| 10. |
|
|
| 11. |
- Akiba, K., et al.
(author)
-
LHC forward physics
- 2016
-
In: Journal of Physics G: Nuclear and Particle Physics. - : IOP Publishing. - 0954-3899 .- 1361-6471. ; 43:11
-
Journal article (peer-reviewed)
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
- MacDonald, K., et al.
(author)
-
Minimization of Childhood Maltreatment Is Common and Consequential: Results from a Large, Multinational Sample Using the Childhood Trauma Questionnaire
- 2016
-
In: Plos One. - : Public Library of Science (PLoS). - 1932-6203. ; 11:1
-
Journal article (peer-reviewed)abstract
- Childhood maltreatment has diverse, lifelong impact on morbidity and mortality. The Childhood Trauma Questionnaire (CTQ) is one of the most commonly used scales to assess and quantify these experiences and their impact. Curiously, despite very widespread use of the CTQ, scores on its Minimization-Denial (MD) subscale-originally designed to assess a positive response bias-are rarely reported. Hence, little is known about this measure. If response biases are either common or consequential, current practices of ignoring the MD scale deserve revision. Therewith, we designed a study to investigate 3 aspects of minimization, as defined by the CTQ's MD scale: 1) its prevalence; 2) its latent structure; and finally 3) whether minimization moderates the CTQ's discriminative validity in terms of distinguishing between psychiatric patients and community volunteers. Archival, item-level CTQ data from 24 multinational samples were combined for a total of 19,652 participants. Analyses indicated: 1) minimization is common; 2) minimization functions as a continuous construct; and 3) high MD scores attenuate the ability of the CTQ to distinguish between psychiatric patients and community volunteers. Overall, results suggest that a minimizing response bias-as detected by the MD subscale-has a small but significant moderating effect on the CTQ's discriminative validity. Results also may suggest that some prior analyses of maltreatment rates or the effects of early maltreatment that have used the CTQ may have underestimated its incidence and impact. We caution researchers and clinicians about the widespread practice of using the CTQ without the MD or collecting MD data but failing to assess and control for its effects on outcomes or dependent variables.
|
|
| 15. |
- Pfeffer, M. G., et al.
(author)
-
Palladium versus Platinum: The Metal in the Catalytic Center of a Molecular Photocatalyst Determines the Mechanism of the Hydrogen Production with Visible Light
- 2015
-
In: Angewandte Chemie-International Edition. - : Wiley. - 1433-7851 .- 1521-3773. ; 54:17, s. 5044-5048
-
Journal article (peer-reviewed)abstract
- To develop highly efficient molecular photocatalysts for visible light-driven hydrogen production, a thorough understanding of the photophysical and chemical processes in the photocatalyst is of vital importance. In this context, in situ X-ray absorption spectroscopic (XAS) investigations show that the nature of the catalytically active metal center in a (N boolean AND N)MCl2 (M=Pd or Pt) coordination sphere has a significant impact on the mechanism of the hydrogen formation. Pd as the catalytic center showed a substantially altered chemical environment and a formation of metal colloids during catalysis, whereas no changes of the coordination sphere were observed for Pt as catalytic center. The high stability of the Pt center was confirmed by chloride addition and mercury poisoning experiments. Thus, for Pt a fundamentally different catalytic mechanism without the involvement of colloids is confirmed.
|
|
| 16. |
- Pironi, L., et al.
(author)
-
Clinical classification of adult patients with chronic intestinal failure due to benign disease: An international multicenter cross-sectional survey
- 2018
-
In: Clinical Nutrition. - : Elsevier BV. - 0261-5614. ; 37:2, s. 728-738
-
Journal article (peer-reviewed)abstract
- Background & aims: The aim of the study was to evaluate the applicability of the ESPEN 16-category clinical classification of chronic intestinal failure, based on patients' intravenous supplementation (IVS) requirements for energy and fluids, and to evaluate factors associated with those requirements. Methods: ESPEN members were invited to participate through ESPEN Council representatives. Participating centers enrolled adult patients requiring home parenteral nutrition for chronic intestinal failure on March 1st 2015. The following patient data were recorded though a structured database: sex, age, body weight and height, intestinal failure mechanism, underlying disease, IVS volume and energy need. Results: Sixty-five centers from 22 countries enrolled 2919 patients with benign disease. One half of the patients were distributed in 3 categories of the ESPEN clinical classification. 9% of patients required only fluid and electrolyte supplementation. IVS requirement varied considerably according to the pathophysiological mechanism of intestinal failure. Notably, IVS volume requirement represented loss of intestinal function better than IVS energy requirement. A simplified 8 category classification of chronic intestinal failure was devised, based on two types of IVS (either fluid and electrolyte alone or parenteral nutrition admixture containing energy) and four categories of volume. Conclusions: Patients' IVS requirements varied widely, supporting the need for a tool to homogenize patient categorization. This study has devised a novel, simplified eight category IVS classification for chronic intestinal failure that will prove useful in both the clinical and research setting when applied together with the underlying pathophysiological mechanism of the patient's intestinal failure. (C) 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
|
|
| 17. |
- Abel, Andreas, 1974, et al.
(author)
-
POPLMark reloaded: Mechanizing proofs by logical relations
- 2019
-
In: Journal of Functional Programming. - : Cambridge University Press (CUP). - 0956-7968 .- 1469-7653. ; 29
-
Journal article (peer-reviewed)abstract
- We propose a new collection of benchmark problems in mechanizing the metatheory of programming languages, in order to compare and push the state of the art of proof assistants. In particular, we focus on proofs using logical relations (LRs) and propose establishing strong normalization of a simply typed calculus with a proof by Kripke-style LRs as a benchmark. We give a modern view of this well-understood problem by formulating our LR on well-typed terms. Using this case study, we share some of the lessons learned tackling this problem in different dependently typed proof environments. In particular, we consider the mechanization in Beluga, a proof environment that supports higher-order abstract syntax encodings and contrast it to the development and strategies used in general-purpose proof assistants such as Coq and Agda. The goal of this paper is to engage the community in discussions on what support in proof environments is needed to truly bring mechanized metatheory to the masses and engage said community in the crafting of future benchmarks.
|
|
| 18. |
- Bengtsson, S., et al.
(author)
-
Space–time control of free induction decay in the extreme ultraviolet
- 2017
-
In: Nature Photonics. - : Springer Science and Business Media LLC. - 1749-4885 .- 1749-4893. ; 11:4, s. 252-258
-
Journal article (peer-reviewed)abstract
- Ultrafast extreme-ultraviolet (XUV) and X-ray sources are revolutionizing our ability to follow femtosecond processes with ångström-scale resolution. The next frontier is to simultaneously control the direction, duration and timing of such radiation. Here, we demonstrate a fully functional opto-optical modulator for XUV light, similar to modulators available at infrared (IR) and visible wavelengths. It works by using an IR pulse to control the spatial and spectral phase of the free induction decay that results from using attosecond pulses to excite a gas. The modulator allows us to send the XUV light in a direction of our choosing at a time of our choosing. The inherent synchronization of the XUV emission to the control pulse will allow laser-pump/X-ray probe experiments with sub-femtosecond time resolution.
|
|
| 19. |
|
|
| 20. |
- Carlström, Stefanos, et al.
(author)
-
Spatially and spectrally resolved quantum path interference with chirped driving pulses
- 2016
-
In: New Journal of Physics. - : IOP Publishing. - 1367-2630. ; 18:12
-
Journal article (peer-reviewed)abstract
- We measure spectrally and spatially resolved high-order harmonics generated in argon using chirped multi-cycle laser pulses. Using a stable, high-repetition rate laser we observe detailed interference structures in the far-field. The structures are of two kinds; off-axis interference from the long trajectory only and on-axis interference including the short and long trajectories. The former is readily visible in the far-field spectrum, modulating both the spectral and spatial profile. To access the latter, we vary the chirp of the fundamental, imparting different phases on the different trajectories, thereby changing their relative phase. Using this method together with an analytical model, we are able to explain the on-axis behaviour and access the dipole phase parameters for the short (${\alpha }_{{\rm{s}}}$) and long (${\alpha }_{{\rm{l}}}$) trajectories. The extracted results compare very well with phase parameters calculated by solving the time-dependent Schrödinger equation. Going beyond the analytical model, we are also able to successfully reproduce the off-axis interference structure.
|
|
| 21. |
- Guo, Chen, et al.
(author)
-
Phase control of attosecond pulses in a train
- 2018
-
In: Journal of Physics B: Atomic, Molecular and Optical Physics. - : IOP Publishing. - 0953-4075 .- 1361-6455. ; 51:3
-
Journal article (peer-reviewed)abstract
- Ultrafast processes in matter can be captured and even controlled by using sequences of few-cycle optical pulses, which need to be well characterized, both in amplitude and phase. The same degree of control has not yet been achieved for few-cycle extreme ultraviolet pulses generated by high-order harmonic generation (HHG) in gases, with duration in the attosecond range. Here, we show that by varying the spectral phase and carrier-envelope phase (CEP) of a high-repetition rate laser, using dispersion in glass, we achieve a high degree of control of the relative phase and CEP between consecutive attosecond pulses. The experimental results are supported by a detailed theoretical analysis based upon the semi-classical three-step model for HHG.
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
- Pfeifer, H., et al.
(author)
-
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
- 2019
-
In: Leukemia. - : NATURE PUBLISHING GROUP. - 0887-6924 .- 1476-5551. ; 33:8, s. 1910-1922
-
Journal article (peer-reviewed)abstract
- Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. Standardised use of EAC primer/probe sets and of centrally prepared plasmid standards had the greatest impact on reducing interlaboratory variability. In QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log difference were 40/67 (60%) and 52/67 (78%) at 10(-3) and 36/67 (53%) and 53/67 (79%) at 10(-4)BCR-ABL1/ABL1. Standardized RNA extraction, cDNA synthesis and cycler platforms did not improve results further, whereas stringent application of technical criteria for assay quality and uniform criteria for data interpretation and reporting were essential. We provide detailed laboratory recommendations for the standardized MRD analysis in routine diagnostic settings and in multicenter clinical trials for Ph + ALL.
|
|
| 25. |
- Salzer, HJF, et al.
(author)
-
Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia
- 2018
-
In: Respiration. - : S. Karger AG. - 1423-0356 .- 0025-7931. ; 96:1, s. 52-65
-
Journal article (peer-reviewed)abstract
- The substantial decline in the <i>Pneumocystis jirovecii</i> pneumonia (PCP) incidence in HIV-infected patients after the introduction of antiretroviral therapy (ART) in resource-rich settings and the growing number of non-HIV-infected immunocompromised patients at risk leads to considerable epidemiologic changes with clinical, diagnostic, and treatment consequences for physicians. HIV-infected patients usually develop a subacute course of disease, while non-HIV-infected immunocompromised patients are characterized by a rapid disease progression with higher risk of respiratory failure and higher mortality. The main symptoms usually include exertional dyspnea, dry cough, and subfebrile temperature or fever. Lactate dehydrogenase may be elevated. Typical findings on computed tomography scans of the chest are bilateral ground-glass opacities with or without cystic lesions, which are usually associated with the presence of AIDS. Empiric treatment should be initiated as soon as PCP is suspected. Bronchoalveolar lavage has a higher diagnostic yield compared to induced sputum. Immunofluorescence is superior to conventional staining. A combination of different diagnostic tests such as microscopy, polymerase chain reaction, and (1,3)-β-D-glucan is recommended. Trimethoprim/sulfamethoxazole for 21 days is the treatment of choice in adults and children. Alternative treatment regimens include dapsone with trimethoprim, clindamycin with primaquine, atovaquone, or pentamidine. Patients with moderate to severe disease should receive adjunctive corticosteroids. In newly diagnosed HIV-infected patients with PCP, ART should be initiated as soon as possible. In non-HIV-infected immunocompromised patients, improvement of the immune status should be discussed (e.g., temporary reduction of immunosuppressive agents). PCP prophylaxis is effective and depends on the immune status of the patient and the underlying immunocompromising disease.
|
|
